Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of ...

COPD requires regular monitoring through tests like spirometry to assess the condition’s severity and aid in an individualized treatment plan. COPD is a progressive lung condition that makes ...

It is important that clinicians are able to stratify disease severity and exacerbation risk in treatment for patients with chronic obstructive pulmonary disease (COPD), says Klaus Rabe ...

Opens in a new tab or window The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on ...

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

Although there is no cure for COPD and new drugs still need to be developed, current treatment options such as statins may still benefit more patients if caregivers become more aware of their ...

The data demonstrated that brensocatib was effective in reducing pulmonary exacerbations regardless of baseline disease severity, suggesting potential for earlier use in the treatment paradigm.

On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

Dupixent is an “add-on” drug for COPD, meaning patients take it in addition to inhaled medication Dupixent isn’t approved as a stand-alone treatment for COPD. The U.S. Food and Drug ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

With the label expansion, Dupixent becomes the first biologic treatment for COPD patients in the U.S. The IL-4 and IL-13 inhibitor is approved to be used as an add-on maintenance treatment by ...

Dupixent for the treatment of COPD has been approved in more than 30 countries across the world, including the 27 countries in the European Union. Sanofi NewsMORE Related Stocks Indices ...